Idarucizumab clinical trials
Also written BI 655075.
How each study uses idarucizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Oct 2015 · PRAXBIND · BLA 761025 (FDA, Drugs@FDA)
- European Union
- 20 Nov 2015 · Praxbind · EMEA/H/C/003986 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses idarucizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are BleedingCompletedPhase 3Boehringer IngelheimNCT03343704Written as Idarucizumab
- Reversal Dabigatran Anticoagulant Effect With IdarucizumabCompletedPhase 3Boehringer IngelheimNCT02815670Written as Idarucizumab
- Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady StateCompletedPhase 1Boehringer IngelheimNCT03086356Written as Idarucizumab
- CU Programme of Idarucizumab for Japanese PatientsCompletedPhase 3Boehringer IngelheimNCT02831660Written as idarucizumab
- Reversal of Dabigatran Anticoagulant Effect With IdarucizumabCompletedPhase 3Boehringer IngelheimNCT02104947Written as idarucizumab
- Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran EtexilateCompletedPhase 1Boehringer IngelheimNCT01688830Written as BI 655075
- Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by DabigatranCompletedPhase 1Boehringer IngelheimNCT01955720Written as BI 655075
Given beside what is tested · 1 — idarucizumab is usual care or a partner of the new treatment
Codes
What other systems call idarucizumab · ClinicalTrials.gg INT000155
- MeSH (NLM) C000594745idarucizumabOne source NLM
- UNII (FDA) 97RWB5S1U6IDARUCIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1716191Confirmed FDA, Wikidata
- Wikidata Q17630273IdarucizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C128646IdarucizumabOne source FDA
- DrugBank DB09264One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000594745 | idarucizumab | One source NLM |
| UNII (FDA) | 97RWB5S1U6 | IDARUCIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1716191 | — | Confirmed FDA, Wikidata |
| Wikidata | Q17630273 | Idarucizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C128646 | Idarucizumab | One source FDA |
| DrugBank | DB09264 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.